Galenea Corp. has aligned its strategy to focus exclusively on discovering and developing drugs to treat central nervous system (CNS) diseases. In line with this focus, Galenea recently agreed to sell its siRNA program for the treatment of influenza and other respiratory viruses to Nastech Pharmaceuticals. The value created by the siRNA program will enable the company to in-license additional CNS programs to augment its pipeline. Galenea will continue to support the research collaboration w...